医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mannatech Brings Ambrotose® Powders to China with Launch of Cross-Border E-commerce Operations

2016年12月14日 AM09:30
このエントリーをはてなブックマークに追加


 

GUANGZHOU, China

Mannatech®, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, announced its cross-border e-commerce launch in China, bringing 15 new products, including its Ambrotose powders, to the Asia market. Mannatech’s innovative Glyconutritional Ambrotose supplement powders have been clinically shown to provide cognitive support, including improved focus, attention and memory for adults, which are key factors to success at school and at work.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161213005152/en/

Mannatech's Advanced Ambrotose powder (Photo: Business Wire)

Mannatech’s Advanced Ambrotose powder (Photo: Business Wire)

According to clinical research funded by Mannatech, randomized, double-blind, placebo-controlled human clinical trials conducted by independent researchers and published in peer reviewed journals have shown that Ambrotose powders can improve memory and positively impact brainwaves associated with attention in young adults and improve memory and reduce cognitive fatigue in middle-aged adults. The positive impact from Ambrotose helps support student achievement as well as adults working long hours who need to stay focused. Clinical studies have also found that Ambrotose powder provides perceived beneficial changes in well-being and supports the immune system.

Ambrotose powder is made with aloe vera gel including Manapol® powder, a unique Glyconutrient ingredient exclusive to Mannatech. Manapol is extracted from fresh, washed and filtered aloe gel through a proprietary extraction method that yields the highest potency possible.

“This is an exciting new product offering for young adults and families in China,” said Dr. Rolando L. Maddela, MHP, CCRP, Mannatech’s Senior Director of Clinical Research and Scientific Affairs. “Improved focus, attention and memory are important components of healthy cognitive function, and Mannatech’s Ambrotose products can offer a positive addition to their regular health and wellness regimen. Specifically, Ambrotose can support those seeking a way to have an edge at their job or in school.”

Dr. Maddela suggests that four grams per day of Advanced Ambrotose® powder or Ambrotose Complex powder can help support some of the factors that contribute to improved cognitive function.

Mannatech is the pioneer in developing Glyconutritional technology, which includes Ambrotose powders. Some of Mannatech’s core products are supported by industry-standard clinical studies, including 17 human clinical trials that have been published, 12 of which were double-blind, placebo-controlled studies — the gold standard for product validation. Mannatech’s nutritional technology has 123 patents in global markets, helping ensure Mannatech’s high standards are maintained throughout the world. Additionally, Mannatech products maintain the highest possible standards with many of the Ambrotose products certified for quality by NSF International.

Advanced Ambrotose and Ambrotose Complex powders have been clinically shown to improve cognitive function and support the body’s immune system. From Mannatech’s e-commerce site in China, shoppers can now purchase these products directly from the website and refer friends and family to shop. Please visit www.MeiTaiChina.com for details.

About Mannatech

Mannatech, Incorporated, offers a profound wellness experience that makes a difference in the lives of people across the world. Through its innovative Glyconutrition products, Mannatech changes lives, providing an unprecedented level of natural wellness. With more than 20 years of experience and operations in more than 25 countries, Mannatech is committed to transforming lives. For more information, visit www.MeiTaiChina.com.

Please note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161213005152/en/

CONTACT

Mannatech, Incorporated
Kalyn Dabbs, 972-471-7245
pr@mannatech.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Konica Minolta and Innovation Network Corporation of Japan Close Acquisition of Ambry Genetics
  • Median Technologies Appoints Vivian Wang as General Manager, China and Takashi Hayashi as Managing Director, Japan
  • Second Sight Announces Appointments of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific; Gregoire Cosendai as Vice President, Clinical Affairs
  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″